Collagen signature adds prognostically significant information to staging for breast cancer.

IF 7.1 2区医学 Q1 ONCOLOGY

ESMO Open Pub Date : 2024-11-21 DOI:10.1016/j.esmoop.2024.103990

Z Li, D Kang, S Xu, G Xi, L Li, L Zheng, W Guo, F Fu, C Wang, J Ma, X Han, S Xu, J Chen, J Chen

{"title":"Collagen signature adds prognostically significant information to staging for breast cancer.","authors":"Z Li, D Kang, S Xu, G Xi, L Li, L Zheng, W Guo, F Fu, C Wang, J Ma, X Han, S Xu, J Chen, J Chen","doi":"10.1016/j.esmoop.2024.103990","DOIUrl":null,"url":null,"abstract":"Background: Tumor-associated collagen signature (TACS) is an independent prognostic factor for breast cancer. However, it is unclear whether the complete collagen signature, including TACS, the TACS-based collagen microscopic features (TCMF1), and the TACS-based nuclear features (TCMF2), can provide additional prognostic information for the current tumor-node-metastasis (TNM) staging system.Patients and methods: We included 941 patients with breast cancer from three cohorts: the training (n = 355), internal (n = 334), and external validation cohorts (n = 252). TACS and TCMF1 were obtained by multiphoton microscopy (MPM). TCMF2 was extracted on the hematoxylin and eosin images colocated with MPM images. They were linearly combined to establish a complete collagen signature score for reclassifying current TNM staging into stage Ⅰ (II and Ⅲ)/low risk and stage Ⅰ (II and Ⅲ)/high risk.Results: The low-risk collagen signatures 'downstaged' patients in stage II or Ⅲ, while the high-risk collagen signatures 'upstaged' patients with stage Ⅰ tumors. After incorporating the complete collagen signature into the current TNM staging system, the modified staging system had a higher ability to stratify patients [referent, Ⅰ-new; Ⅱ-new, hazard ratio (HR) 8.655, 6.136, and 4.699 in the training, internal validation, and external validation cohorts, respectively; Ⅲ-new, HR 14.855, 11.201, and 13.245 in the corresponding three cohorts, respectively] than the current TNM staging system (referent, Ⅰ; Ⅱ, HR 1.642, 1.853, and 1.371 in the corresponding three cohorts, respectively; Ⅲ, HR 4.131, 4.283, and 3.711 in the corresponding three cohorts, respectively). Furthermore, the modified staging system showed a higher area under the curve than the current TNM staging system (training cohort: 0.843 versus 0.683; internal validation cohort: 0.792 versus 0.661; and external validation cohort: 0.793 versus 0.646).Conclusions: The complete collagen signature is an independent predictor of survival outcomes in breast cancer. It adds significant information about the biological behavior of the disease to staging for breast cancer.","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 12","pages":"103990"},"PeriodicalIF":7.1000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.esmoop.2024.103990","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tumor-associated collagen signature (TACS) is an independent prognostic factor for breast cancer. However, it is unclear whether the complete collagen signature, including TACS, the TACS-based collagen microscopic features (TCMF1), and the TACS-based nuclear features (TCMF2), can provide additional prognostic information for the current tumor-node-metastasis (TNM) staging system.

Patients and methods: We included 941 patients with breast cancer from three cohorts: the training (n = 355), internal (n = 334), and external validation cohorts (n = 252). TACS and TCMF1 were obtained by multiphoton microscopy (MPM). TCMF2 was extracted on the hematoxylin and eosin images colocated with MPM images. They were linearly combined to establish a complete collagen signature score for reclassifying current TNM staging into stage Ⅰ (II and Ⅲ)/low risk and stage Ⅰ (II and Ⅲ)/high risk.

Results: The low-risk collagen signatures 'downstaged' patients in stage II or Ⅲ, while the high-risk collagen signatures 'upstaged' patients with stage Ⅰ tumors. After incorporating the complete collagen signature into the current TNM staging system, the modified staging system had a higher ability to stratify patients [referent, Ⅰ-new; Ⅱ-new, hazard ratio (HR) 8.655, 6.136, and 4.699 in the training, internal validation, and external validation cohorts, respectively; Ⅲ-new, HR 14.855, 11.201, and 13.245 in the corresponding three cohorts, respectively] than the current TNM staging system (referent, Ⅰ; Ⅱ, HR 1.642, 1.853, and 1.371 in the corresponding three cohorts, respectively; Ⅲ, HR 4.131, 4.283, and 3.711 in the corresponding three cohorts, respectively). Furthermore, the modified staging system showed a higher area under the curve than the current TNM staging system (training cohort: 0.843 versus 0.683; internal validation cohort: 0.792 versus 0.661; and external validation cohort: 0.793 versus 0.646).

Conclusions: The complete collagen signature is an independent predictor of survival outcomes in breast cancer. It adds significant information about the biological behavior of the disease to staging for breast cancer.

查看原文本刊更多论文

胶原蛋白特征为乳腺癌分期提供了重要的预后信息。

背景：肿瘤相关胶原特征（TACS）是乳腺癌的一个独立预后因素。然而，完整的胶原特征（包括 TACS、基于 TACS 的胶原显微特征（TCMF1）和基于 TACS 的核特征（TCMF2））能否为当前的肿瘤-结节-转移（TNM）分期系统提供额外的预后信息，目前尚不清楚：我们纳入了来自三个队列的 941 名乳腺癌患者：训练队列（n = 355）、内部队列（n = 334）和外部验证队列（n = 252）。TACS和TCMF1通过多光子显微镜（MPM）获得。TCMF2 是在与 MPM 图像同位的苏木精和伊红图像上提取的。将它们线性组合，建立完整的胶原特征评分，用于将目前的TNM分期重新分为Ⅰ期（Ⅱ和Ⅲ期）/低危和Ⅰ期（Ⅱ和Ⅲ期）/高危：低风险胶原特征 "降低 "了Ⅱ期或Ⅲ期患者的分期，而高风险胶原特征则 "提高 "了Ⅰ期患者的分期。将完整的胶原特征纳入当前的 TNM 分期系统后，修改后的分期系统对患者的分层能力更强[参照组，Ⅰ-新；Ⅱ-新，在训练组、内部验证组和外部验证组中的危险比（HR）分别为 8.655、6.136 和 4.699；Ⅲ-新，HR 为 14.与目前的 TNM 分期系统（参考，Ⅰ；Ⅱ，HR 分别为 1.642，1.853 和 1.371；Ⅲ，HR 分别为 4.131，4.283 和 3.711）相比，Ⅲ-新分期系统的 HR 分别为 14.855，11.201 和 13.245。）此外，改良分期系统的曲线下面积高于现行的TNM分期系统（培训队列：0.843对0.683；内部验证队列：0.792对0.661；外部验证队列：0.793对0.646）：结论：完整的胶原蛋白特征是乳腺癌生存结果的独立预测指标。结论：完整的胶原蛋白特征是乳腺癌生存结果的独立预测指标，它为乳腺癌分期增加了有关疾病生物学行为的重要信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ESMO Open Medicine-Oncology

CiteScore

11.70

自引率

2.70%

发文量

255

审稿时长

10 weeks

期刊介绍： ESMO Open is the online-only, open access journal of the European Society for Medical Oncology (ESMO). It is a peer-reviewed publication dedicated to sharing high-quality medical research and educational materials from various fields of oncology. The journal specifically focuses on showcasing innovative clinical and translational cancer research. ESMO Open aims to publish a wide range of research articles covering all aspects of oncology, including experimental studies, translational research, diagnostic advancements, and therapeutic approaches. The content of the journal includes original research articles, insightful reviews, thought-provoking editorials, and correspondence. Moreover, the journal warmly welcomes the submission of phase I trials and meta-analyses. It also showcases reviews from significant ESMO conferences and meetings, as well as publishes important position statements on behalf of ESMO. Overall, ESMO Open offers a platform for scientists, clinicians, and researchers in the field of oncology to share their valuable insights and contribute to advancing the understanding and treatment of cancer. The journal serves as a source of up-to-date information and fosters collaboration within the oncology community.